Compare SHAK & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | VCEL |
|---|---|---|
| Founded | 2004 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2014 | 1996 |
| Metric | SHAK | VCEL |
|---|---|---|
| Price | $70.23 | $40.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 5 |
| Target Price | ★ $117.29 | $57.75 |
| AVG Volume (30 Days) | ★ 1.6M | 461.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | 60.00 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,445,306,000.00 | $276,259,000.00 |
| Revenue This Year | $16.58 | $19.40 |
| Revenue Next Year | $15.07 | $18.24 |
| P/E Ratio | $190.68 | ★ N/A |
| Revenue Growth | 15.38 | ★ 16.45 |
| 52 Week Low | $51.60 | $28.95 |
| 52 Week High | $107.46 | $49.32 |
| Indicator | SHAK | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 35.71 |
| Support Level | $52.90 | $35.45 |
| Resistance Level | $74.50 | $42.16 |
| Average True Range (ATR) | 2.12 | 1.42 |
| MACD | -0.75 | -0.36 |
| Stochastic Oscillator | 3.36 | 8.83 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.